Clinical trials: cyclosporine
Myeloid Tumor
ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center
A novel regimen, which is composed of a low dose of ATG (5 mg/kg) and low-dose PTCy (one dose of PTCy, 50mg/kg) for GvHD prophylaxis in Haplo-PBSCT for patients with hematologic malignancies, was designed to decrease the risk of…
- Trial name
- ATG/PTCy (NCT03608059)
- Testing
- ATG/PTCy, standard ATG, standard PTCy
- Where
- 6 sites in China
- Volunteers
- 418 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Corneal Transplantation, Corneal Graft Rejection
Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
This study will evaluate the use of LX201 to prevent future graft rejection episodes and/or graft failure in patients who have undergone corneal transplantation and who have recently experienced a rejection episode due to an…
- Trial name
- NCT00447642
- Testing
- LX201
- Where
- 30 sites in United States, Germany
- Volunteers
- 122 people
- Sponsor
- Lux Biosciences, Inc.
Liver Transplant
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
The purpose of this study is to determine whether cyclosporine A (in a micro emulsion formulation) monitored by sample taken 2 hour after oral dose (C-2h) will show equivalent or superior efficacy compared to tacrolimus monitored…
- Trial name
- NCT00149994
- Testing
- Cyclosporine A, Tacrolimus, Basiliximab
- Where
- Switzerland
- Volunteers
- 171 people
- Sponsor
- Novartis Pharmaceuticals
Aplastic Anaemia
Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)
The purpose of this study is to examine the effect of G-CSF on disease free survival and overall survival in aplastic anaemia patients who also receive ATG and Cyclosporin A.
- Trial name
- SAA-G-CSF (NCT01163942)
- Testing
- G-CSF, Early retreatment with ATG
- Where
- 71 sites in Czechia, France and 7 more
- Volunteers
- 205 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Kidney Transplant Recipients
An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients
To evaluate whether maintenance renal transplant patients on micophenolate mofetil (MMF) can be safely converted to EC-MPS, based on adverse events and acute rejection within 6 months after switching from MMF to a EC-MPS regimen.
- Trial name
- NCT00239044
- Testing
- Enteric-coated Mycophenolate sodium (EC-MPS)
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Mycoses, Sezary Syndrome
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given that the median age at diagnosis is 55-60 years and frequently present compromised skin in these patients, which increases the risk of…
- Conditions
- Mycoses, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Bone Marrow Transplant Failure
- Trial name
- NCT00896493
- Testing
- anti-thymocyte globulin, cyclosporine, Lymphoid radiation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Graft Versus Host Disease, Lymphoma
Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease
RATIONALE: Cyclosporine may induce graft-versus-host disease and make the body build an immune response that will kill cancer cells.
- Trial name
- NCT00003414
- Testing
- aldesleukin, recombinant interferon gamma, busulfan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft vs Host Disease, Malignancy
Abatacept as GVHD Prophylaxis Phase 2
This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or…
- Trial name
- NCT01743131
- Testing
- Abatacept
- Where
- 14 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- Boston Children's Hospital
Graft Versus Host Disease in Eye
Evaluation of 0.05% CsA and 0.1% FK506 Eye Drops in Ocular GVHD Treatment
It is planned to explore the efficacy and safety of local 0.05% cyclosporine eye drops in the treatment of chronic graft-versus-host eye disease.
- Trial name
- NCT05294666
- Testing
- Cyclosporine, tacrolimus
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Peking University Third Hospital
Dry Eye Syndromes
Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)
Dry eye disease (DED) is an umbrella term encompassing a range of diseases estimated to affect 14% of all adults aged 48 to 91. If left untreated, DED can lead to severe reduction in the quality of life of the sufferer.
- Trial name
- FAB (NCT03395431)
- Testing
- Fingerprick autologuos blood (FAB)
- Volunteers
- 60 people
- Sponsor
- Bedford Hospital NHS Trust
Severe Aplastic Anemia
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
Background: Severe aplastic anemia (SAA) is a rare and serious blood disorder. It causes the immune system to turn against bone marrow cells.
- Trial name
- NCT04304820
- Testing
- Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Aplastic Anemia, TPO Receptor Agonists
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
This prospective, single center, single-arm study aims to evaluate the efficacy and safety of anti-human T lymphocyte porcine immunoglobulin (p-ALG) in combination with cyclosporine and Romiplostim in treating severe aplastic…
- Trial name
- NCT06613880
- Testing
- standard IST combined with Romiplostim N01
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pemphigus
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug.
- Trial name
- NCT01313923
- Testing
- Sirolimus (formerly known as Rapamycin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, Irvine
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Leukemia (Both ALL and AML), MDS-EB-1
Ikervis for DED Due to GVHD Post Allo-HSCT
Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- Ikervis (NCT04636918)
- Testing
- Cyclosporine Ophthalmic
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore Eye Research Institute
Autism Spectrum Disorder, Eosinophilic Gastrointestinal Disorders
Umbilical Cord Blood Therapy in a Child With Eosinophilic Duodenitis and Autism Spectrum Disorder: a Case Study
This single-case exploratory clinical study aims to evaluate the therapeutic potential of umbilical cord blood (UCB) infusion in a pediatric patient diagnosed with both eosinophilic duodenitis (ED) and autism spectrum disorder…
- Trial name
- NCT06995274
- Testing
- Umbilical Cord Blood Infusion (Autologous and Allogeneic)
- Volunteers
- 1 people
- Sponsor
- Bundang CHA Hospital
Healthy
Drug-Drug Interaction Study: ASP2151 and Ciclosporin
ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue transplantation may be prescribed ciclosporin to suppress their immune system to give the transplant an increased chance of not being rejected.
- Trial name
- NCT02280421
- Testing
- ASP2151 400mg + 100mg ciclosporin, ASP2151 1200mg + 100mg ciclosporin
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Mucopolysaccharidosis I
Immune Tolerance Study With Aldurazyme® (Laronidase)
The purpose of this study is to see if treatment with an antigen-specific immunosuppressive can decrease or stop an antibody response to laronidase (Aldurazyme®) during enzyme replacement therapy with laronidase in severe…
- Trial name
- NCT00741338
- Testing
- Laronidase, Cyclosporine A (CsA), Azathioprine (Aza)
- Where
- 2 sites in Brazil, Russia
- Volunteers
- 7 people
- Sponsor
- Genzyme, a Sanofi Company
Moderate to Severe Dry Eye Syndrome
Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion versus Vehicle in Patients with Moderate to Severe Dry Eye Syndrome
- Trial name
- NCT00814515
- Testing
- NOVA22007 (Ciclosporin 0.1%), NOVA22007
- Where
- France
- Volunteers
- 482 people
- Sponsor
- Santen SAS
Stem Cell Transplantation
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
To assess the outcomes of NRM when administering pharmacologic pretransplant immunosuppression (PTIS) followed by pretransplant reduced toxicity conditioning (RTC) and an allogeneic stem cell transplant (allo-SCT) and…
- Trial name
- NCT05293509
- Testing
- Fludarabine, Dexamethasone, Cyclophosphamide
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.